布地奈德缓释胶囊3mg的价格是多少？

The price of 3mg budesonide sustained-release capsules

The price of 3mg budesonide sustained-release capsules is currently about 1950$ per box, and the specification is the German version of budesonide sustained-release capsules 3mgx100 capsules.

The recommended dose of budesonide extended-release capsules 3 mg for adults is 9 mg orally once daily for 8 weeks. That is to say, 3 pills are needed every day, and one box can last for a month. Patients can calculate the required quantity and cost according to their own situation.

Budesonide sustained-release capsules have not been officially launched in mainland China as of December 4, 2023. They are not yet available in domestic hospital pharmacies, and there is no price announcement.

Patients in need can go to Germany to buy the medicine, but the distance is long, the risk is high, and the corresponding cost will also increase, making it not suitable for long-term medication. When purchasing, patients can purchase budesonide sustained-release capsules at pharmaceutical chain stores or online pharmacies in some large cities, but the price may be relatively high.

Patients can also obtain the drugs through the help of domestic professional overseas medical service institutions. The drugs can be mailed to their homes, which is guaranteed to be genuine and cost-effective. However, it is recommended to consult customer service personnel for specific costs and acquisition procedures.

The effects of 3 mg budesonide sustained-release capsules

Budesonide is a corticosteroid with strong glucocorticoid activity and weak mineralocorticoid activity. Budesonide sustained-release capsules are suitable for patients who have been diagnosed with IgA nephropathy. This medicine is also used to treat mild to moderately active Crohn's disease, including in the ileum and/or ascending colon, in patients 8 years and older. Maintain clinical remission in adults with mild to moderate Crohn's disease, including the ileum and/or ascending colon for up to 3 months.

Therapeutic efficacy of budesonide extended-release capsules

Three randomized, double-blind, placebo-controlled Phase II or III studies (budesonide MMX 9 mg, 6 mg, or 3 mg for 8 weeks), one Phase II study (randomized MMX 9 mg or placebo for 4 weeks, followed by open-label budesonide MMX 9 mg for 4 weeks) and an open-label study (budesonide MMX 9 mg for 8 weeks).

Study results

The incidence of adverse events [AEs] [27.1%, 24.8% and 23.9%, respectively] and the incidence of serious AEs [2.4%, 2.0% and 2.7%, respectively] in patients randomized to receive budesonide MMX 9 mg [n = 288], 6 mg [n = 254] or placebo [n = 293].

Treatment-related AEs and serious AEs were reported in 11.8% and 13.5% and 5.9% and 2.2% of patients receiving budesonide MMX 3 mg [n = 17] or open-label budesonide MMX 9 mg [n = 89], respectively.

Mean morning plasma cortisol concentrations were normal in randomized patients from baseline to final visit; in patients treated with open-label budesonide, mean cortisol concentrations were 129.9 nmol/l after 4 weeks and returned to normal concentrations at final visit. Budesonide MMX is not associated with an increased overall risk of glucocorticoid-related adverse reactions.

Trial Conclusions

Budesonide MMX 9 mg produced normal mean cortisol concentrations at the final visit and an incidence rate comparable to placebo. Overall, budesonide MMX was safe and well tolerated in inducing remission in patients with mild to moderate ulcerative colitis.

Budesonide sustained-release capsules can be used to treat Crohn's disease, ulcerative colitis, and some autoimmune diseases, such as autoimmune hepatitis and nephritis. Before using the drug, you should strictly follow the doctor's instructions and pay attention to the side effects and precautions of the drug.

Recommended hot articles:

References

Lichtenstein GR, Travis S, Danese S, D'Haens G, Moro L, Jones R, Huang M, Ballard ED, Bagin R, Hardiman Y, Collazo R, Sandborn WJ. Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. J Crohns Colitis. 2015 Sep;9(9):738-46. doi: 10.1093/ecco-jcc/jjv101. Epub 2015 Jun 20. PMID: 26094251; PMCID: PMC4736820.